RRx-001 Accelerates Low Dose Oxaliplatin-Induced Cytotoxicity in Triple-Negative Breast Cancer Cells via Synergistic Antitumor Mechanisms
Background: Triple-negative breast cancer (TNBC) represents an aggressive subtype that has few therapeutic options for targeting and is highly resistant to chemotherapy. The compound RRx-001 is a dinitroazetidine compound with both immune-modulating and epigenetic properties, whereas oxaliplatin elicits immunogenic cel...